Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $10.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its target price boosted by Truist Financial from $9.00 to $10.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, The Goldman Sachs Group upped their price objective on Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a buy rating in a research report on Monday, May 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of Buy and an average price target of $9.00.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $7.91 on Monday. The business’s 50 day moving average price is $7.06 and its 200-day moving average price is $6.35. The company has a market cap of $2.44 billion, a P/E ratio of -14.13 and a beta of 1.23. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.97 and a current ratio of 1.65. Amneal Pharmaceuticals has a fifty-two week low of $3.36 and a fifty-two week high of $8.15.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Profund Advisors LLC lifted its holdings in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock worth $143,000 after buying an additional 1,680 shares during the period. ProShare Advisors LLC lifted its holdings in shares of Amneal Pharmaceuticals by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock worth $133,000 after buying an additional 1,726 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Amneal Pharmaceuticals by 18.8% in the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock worth $122,000 after buying an additional 3,177 shares during the period. Rothschild Investment LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Amneal Pharmaceuticals by 13.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares during the period. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.